首页> 美国卫生研究院文献>Indian Journal of Hematology Blood Transfusion >Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etexilate Methanesulfonate: A Case Report and Review of the Literature
【2h】

Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etexilate Methanesulfonate: A Case Report and Review of the Literature

机译:达比加群酯甲磺酸盐治疗后获得性因子V抑制剂的开发:病例报告和文献复习。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 90-year-old man presented with subcutaneous ecchymoses. He had been under treatment with dabigatran etexilate methanesulfonate (DEM). Prolonged APTT and decreased PT was developed 2 months after the start of DEM, more prolonged 6 months later. DEM was discontinued, the coagulopathy did not improve. Factor V activity was decreased, along with appearance of coagulation factor V inhibitor (FVI). He did not have antiphospholipid syndrome or malignancy. He was diagnosed as having acquired FVI caused by DEM. Steroid pulse therapy was effective. There have been 74 reported cases of AFVI induced by drug treatment, but none after treatment with DEM.
机译:一名90岁男子出现皮下瘀斑。他曾接受达比加群酯甲磺酸盐(DEM)的治疗。 DEM开始后2个月出现APTT延长和PT下降,而6个月后又延长了。停用DEM,凝血功能不改善。凝血因子V抑制剂(FVI)的出现降低了凝血因子V的活性。他没有抗磷脂综合症或恶性肿瘤。他被诊断出患有由DEM引起的FVI。类固醇脉冲疗法是有效的。据报道,有74例药物治疗引起的AFVI病例,但用DEM治疗后未发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号